<DOC>
	<DOCNO>NCT00083889</DOCNO>
	<brief_summary>The purpose study test whether SU011248 activity safe compare interferon-alfa first-line therapy patient metastatic renal cell carcinoma ( RCC ) .</brief_summary>
	<brief_title>SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically confirm renal cell carcinoma clear cell histology metastases Evidence measurable disease radiographic technique Eastern Cooperative Oncology Group [ ECOG ] performance status 0 1 Prior systemic ( include adjuvant neoadjuvant ) therapy kind RCC History know brain metastasis Serious acute chronic illness recent history significant cardiac abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>